MarketPulse

patent expiration

12 articles
The Motley FoolThe Motley Fool··David Jagielski, Cpa

AbbVie Stock Trades at Bargain Valuation as New Drugs Offset Humira Decline

AbbVie stock down 11% YTD but trades at 14x forward P/E with 0.49 PEG, suggesting undervaluation amid strong new drug momentum and 3.4% dividend yield.
ABBVXLVdividend yieldhealthcare stocks
The Motley FoolThe Motley Fool··Thomas Niel

FMC Stock at Crossroads: Can Patent Pipeline and M&A Lift Agricultural Chemicals Giant?

FMC stock tumbled two-thirds amid patent expirations and industry headwinds, but potential acquisition and new products could spark recovery.
FMCCFMOSvaluation opportunitystrategic alternatives
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Eli Lilly's GLP-1 Dominance Faces Reality Check as Valuation Reaches Peak Levels

Eli Lilly's GLP-1 drugs drive 56% of revenues with explosive growth, but 43x P/E valuation leaves no room for disappointment amid intensifying competition and future patent risks.
PFELLYNVOGLP-1 drugsweight loss drugs
The Motley FoolThe Motley Fool··Adria Cimino

Pfizer at a Crossroads: Patent Cliffs and Pipeline Bets Define Next Chapter

Pfizer faces patent cliffs and COVID vaccine decline, betting on oncology and obesity drug pipelines to drive future growth amid acquisition integration challenges.
PFELLYNVOclinical trialsacquisitions
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Eli Lilly's GLP-1 Dominance Masks Valuation Risks for Long-Term Investors

Eli Lilly's GLP-1 success masks valuation risks; P/E of 44 leaves little room for competitive pressure and patent cliff execution.
PFELLYNVOGLP-1 drugsgeneric competition
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Amarin's Vascepa Faces Generic Onslaught: Single-Drug Dependency Poses Existential Risk

Amarin's sole drug Vascepa faces generic competition, causing revenue to plummet 36% to $183 million in 2025, raising serious concerns about the company's single-product vulnerability.
PFEAMRNrevenue declinerestructuring
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Eli Lilly's GLP-1 Dominance Masks Valuation Risks; Analysts Eye Cheaper Alternatives

Eli Lilly trades at premium 44 P/E despite GLP-1 concentration risks. Novo Nordisk and Pfizer offer higher yields and lower valuations.
PFELLYNVOvaluationbiotech
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Bristol Myers Squibb's 4% Dividend Could Compound to Seven-Figure Wealth

Bristol Myers Squibb's 4% dividend yield, well above sector averages and trading 25% below 2022 highs, could compound into seven-figure retirement wealth through consistent reinvestment.
BMYCELGrdividend stocksdividend yield
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Pfizer's 6.4% Dividend Yield Attracts Income Investors Despite Sector Headwinds

Pfizer's 6.4% dividend yield attracts income investors, but structural challenges like patent expirations and a payout ratio exceeding 100% present execution risks.
PFEdividend yieldincome investing
BenzingaBenzinga··Vandana Singh

Merck Restructures Commercial Operations Ahead of Keytruda Patent Cliff

Merck restructures commercial operations into two divisions ahead of Keytruda's 2028 patent expiration, aiming to accelerate growth from 20+ pipeline candidates.
MRKrestructuringpatent expiration
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

AbbVie Stock Declines Despite Strong Quarterly Results and Pipeline Growth

AbbVie stock fell despite strong Q4 results and 10% revenue growth. Investors worry about Humira patent expiration, though new drugs Skyrizi and Rinvoq show promise.
ABBVearnings reportdividend stock
The Motley FoolThe Motley Fool··Matthew Benjamin

Eli Lilly Positions Itself as Pharma Leader Through GLP-1 Dominance and Strategic M&A

Eli Lilly strengthens market position through GLP-1 dominance and strategic acquisitions like Orna Therapeutics, diversifying growth beyond patent cliff risks.
PFELLYacquisitionsgene therapy